Motes early tumor dissemination by means of complexing with activated 1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene 33:25568. 17. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM (2009) The transmembrane src substrate Trask is definitely an epithelial protein that signals in the course of anchorage deprivation. Am J Pathol 174:1756765. 18. Conze T, et al. (2003) CDCP1 is often a novel marker for hematopoietic stem cells. Ann N Y Acad Sci 996:22226. 19. B ring HJ, et al. (2004) CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells 22:33443. 20. Uekita T, Sakai R (2011) Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis. Cancer Sci 102:1943948.E6920 | et al.21. Perry SE, et al. (2007) Expression in the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett 581:1137142. 22. Uekita T, et al. (2008) CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. Am J Pathol 172:1729739. 23. Awakura Y, et al. (2008) Microarray-based identification of CUB-domain containing protein 1 as a possible prognostic marker in conventional renal cell carcinoma. J Cancer Res Clin Oncol 134:1363369. 24. Razorenova OV, et al. (2011) VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCdelta-driven migration. Proc Natl Acad Sci USA 108:1931936. 25. Wong CH, et al. (2009) Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in regular epithelia but widespread in many human epithelial cancers. Clin Cancer Res 15:2311322. 26. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM (2013) Trask loss enhances tumorigenic growth by liberating integrin signaling and development factor receptor crosstalk in unanchored cells. Cancer Res 73:1168179. 27. Jayaraman K (2013) Biocon’s first-in-class anti-CD6 mAb reaches the market.TRAIL/TNFSF10 Protein manufacturer Nat Biotechnol 31:1062063.IL-1beta, Human (solution) 28.PMID:25959043 Seidel J, Bruemann C, Kunc K, Possinger K, Lueftner D (2009) Evaluation of CUBdomain-containing protein (CDCP1)-expression as predictive marker of adhesionindependent cell survival in breast cancer cell lines. Cancer Res 69:6167. 29. Wortmann A, et al. (2011) Cellular settings mediating Src Substrate switching in between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem 286:423032315. 30. Kollmorgen G, et al. (2013) Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol 7:1142151. 31. Ikeda JI, et al. (2006) Epigenetic regulation with the expression from the novel stem cell marker CDCP1 in cancer cells. J Pathol 210:754. 32. Spassov DS, et al. (2011) Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol 31: 76682. 33. Lunter Pc, et al. (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166/ MEMD), a novel actor in invasive development, controls matrix metalloproteinase activity. Cancer Res 65:8801808. 34. Miyazawa Y, et al. (2010) CUB domain-containing protein 1, a prognostic element for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 70:5136146. 35. Li Y, et al. (2017) CD6 as a potential target for treating numerous sclerosis. Proc Natl Acad Sci USA 114:2687692. 36. Singer NG, et al. (1997) CD6.